LMB89 treatment courses
| Regimen . | Daily dose . | Administration . | Days . |
|---|---|---|---|
| Prephase | |||
| COP | |||
| CPM | 0.3 g/m2 | IV | 1 |
| VCR | 1 mg/m2 | IV | 1 |
| Prednisone | 60 mg/m2 | IV or orally (in 2 fractions) | 1-7 |
| MTX + HC (gr C: + Ara-C) | 15 mg (gr C: + 30 mg) | IT | 1 (gr C: + 3 + 5) |
| Induction phase | |||
| COPADM no. 1, started 1 wk after first day of prephase | |||
| VCR | 2 mg/m2 (max 2 mg) | IV | 1 |
| HDMTX | B: 3 g/m2 (gr C: 8 g/m2) | IV 3 h (gr C: 4 h) | 1 |
| CFR | 15 mg/m2 every 6 h | Orally | 2, 3, 4 |
| MTX + HC (gr C: + Ara-C) | 15 mg (gr C: + 30 mg) | IT | 2, 6 (gr C: + 4) |
| ADR | 60 mg/m2 | IV | 2 |
| Cyclophosphamide | 0.5 g/m2 | IV (in 2 fractions) | 2, 3, 4 |
| Prednisone | 60 mg/m2 | IV or orally | 1-6 |
| COPADM no. 2, similar to COPADM no. 1 except for: | |||
| Second VCR dose | 2 mg/m2(max 2 mg) | IV | 6 |
| Cyclophosphamide | 1 g/m2 | IV (in 2 fractions) | 2, 3, 4 |
| COPAD (group A), similar to COPADM no. 1, but without HDMTX and IT and with additional dose of VCR | 2 mg/m2 (max 2 mg) | IV | 6 |
| Consolidation phase | |||
| Group B: CYM no. 1 and 2 | |||
| HDMTX | 3 g/m2 | IV (3 h) | 1 |
| CFR | 15 mg/m2 every 6 h | Orally | 2, 3, 4 |
| MTX + HC | 15 mg | IT | 2 |
| Ara-C | 100 mg/m2 | CI (24 h) | 2-6 |
| Ara-C + HC | 30 mg + 15 mg | IT | 6 |
| Group C: CYVE no. 1 and 2 | |||
| Ara-C | 50 mg/m2 | CI (12 h) | 1-5(8 pm-8 am) |
| HDAra-C | 3 g/m2 | IV (3 h) | 2-5 (8-11 am) |
| VP-16 | 200 mg/m2 | IV | 2-5 (2-4pm) |
| Maintenance (monthly alternated courses) | |||
| m1 | |||
| VCR | 2 mg/m2 (max 2 mg) | IV | 1 |
| HDMTX | B: 3 g/m2 (gr C: 8 g/m2) | IV 3 h (gr C: 4 h) | 1 |
| CFR | 15 mg/m2 every 6 h | Orally | 2-4 |
| Prednisone | 60 mg/m2 | Orally | 1-5 |
| MTX + HC (gr C: + Ara-C) | 15 mg (gr C: + 30 mg) | IT | 2 |
| Cyclophosphamide | 0.5 g/m2 | IV | 1, 2 |
| ADR | 60 mg/m2 | IV | 2 |
| m3, similar to m1 but without HDMTX and IT | |||
| m2 or m4 | |||
| VP-16 | 150 mg/m2 | IV | 1-3 |
| Ara-C | 100 mg/m2 | SC (in 2 fractions) | 1-5 |
| Regimen . | Daily dose . | Administration . | Days . |
|---|---|---|---|
| Prephase | |||
| COP | |||
| CPM | 0.3 g/m2 | IV | 1 |
| VCR | 1 mg/m2 | IV | 1 |
| Prednisone | 60 mg/m2 | IV or orally (in 2 fractions) | 1-7 |
| MTX + HC (gr C: + Ara-C) | 15 mg (gr C: + 30 mg) | IT | 1 (gr C: + 3 + 5) |
| Induction phase | |||
| COPADM no. 1, started 1 wk after first day of prephase | |||
| VCR | 2 mg/m2 (max 2 mg) | IV | 1 |
| HDMTX | B: 3 g/m2 (gr C: 8 g/m2) | IV 3 h (gr C: 4 h) | 1 |
| CFR | 15 mg/m2 every 6 h | Orally | 2, 3, 4 |
| MTX + HC (gr C: + Ara-C) | 15 mg (gr C: + 30 mg) | IT | 2, 6 (gr C: + 4) |
| ADR | 60 mg/m2 | IV | 2 |
| Cyclophosphamide | 0.5 g/m2 | IV (in 2 fractions) | 2, 3, 4 |
| Prednisone | 60 mg/m2 | IV or orally | 1-6 |
| COPADM no. 2, similar to COPADM no. 1 except for: | |||
| Second VCR dose | 2 mg/m2(max 2 mg) | IV | 6 |
| Cyclophosphamide | 1 g/m2 | IV (in 2 fractions) | 2, 3, 4 |
| COPAD (group A), similar to COPADM no. 1, but without HDMTX and IT and with additional dose of VCR | 2 mg/m2 (max 2 mg) | IV | 6 |
| Consolidation phase | |||
| Group B: CYM no. 1 and 2 | |||
| HDMTX | 3 g/m2 | IV (3 h) | 1 |
| CFR | 15 mg/m2 every 6 h | Orally | 2, 3, 4 |
| MTX + HC | 15 mg | IT | 2 |
| Ara-C | 100 mg/m2 | CI (24 h) | 2-6 |
| Ara-C + HC | 30 mg + 15 mg | IT | 6 |
| Group C: CYVE no. 1 and 2 | |||
| Ara-C | 50 mg/m2 | CI (12 h) | 1-5(8 pm-8 am) |
| HDAra-C | 3 g/m2 | IV (3 h) | 2-5 (8-11 am) |
| VP-16 | 200 mg/m2 | IV | 2-5 (2-4pm) |
| Maintenance (monthly alternated courses) | |||
| m1 | |||
| VCR | 2 mg/m2 (max 2 mg) | IV | 1 |
| HDMTX | B: 3 g/m2 (gr C: 8 g/m2) | IV 3 h (gr C: 4 h) | 1 |
| CFR | 15 mg/m2 every 6 h | Orally | 2-4 |
| Prednisone | 60 mg/m2 | Orally | 1-5 |
| MTX + HC (gr C: + Ara-C) | 15 mg (gr C: + 30 mg) | IT | 2 |
| Cyclophosphamide | 0.5 g/m2 | IV | 1, 2 |
| ADR | 60 mg/m2 | IV | 2 |
| m3, similar to m1 but without HDMTX and IT | |||
| m2 or m4 | |||
| VP-16 | 150 mg/m2 | IV | 1-3 |
| Ara-C | 100 mg/m2 | SC (in 2 fractions) | 1-5 |
Italics indicate specific to group C.
COP indicates cyclophosphamide, Oncovin (vincristine), prednisone; CPM, cyclophosphamide; IV, intravenous; VCR, vincristine (maximum dose, 2 mg by injection); MTX, methotrexate; HC, hydrocortisone; Ara-C, cytarabine; IT, intrathecal; COPADM, cyclophosphamide, Oncovin (vincristine), prednisone, adriamycin (doxorubicin), methotrexate; HD, high dose; CFR, citrovorum factor rescue (leucovorin); ADR, adriamycin (doxorubicin); CYM, cytarabine (Ara-c), methotrexate; CI, continuous infusion; CYVE, cytarabine (Ara-c), VP-16 (etoposide); SC, subcutaneously.